USA: New autogenous aMPV vaccines
The MSD Animal Health company recently announced that the United States Department of Agriculture (USDA) has approved the production and sale of an experimental autogenous vaccine, developed by Cambridge Technology, targeting avian metapneumovirus (aMPV) type B. This strain has been impacting turkeys, broilers, and layers since November 2023. Cambridge Technology specializes in the development of autogenous vaccines, utilizing advanced biotechnologies to tailor vaccines to the specific needs of livestock farms. The company operates a production facility in Minnesota, USA.
CEVA has also initiated the production of an autogenous vaccine targeting the aMPV type B. CEVA has reported that its next objective is the development of a bivalent vaccine, which will include both type A and type B strains, as both have been implicated in the current outbreaks across the United States. The CEVA vaccine is currently undergoing production, with regulatory approvals expected to be completed in the coming weeks.
No commercially licensed vaccines are available in the US.
